RegeneRx Awarded Australian Patent for New TB4 Applications
08 Julho 2010 - 9:30AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex: RGN) (the
“Company” or “RegeneRx”) today announced it has received Notice of
Acceptance from the Australian patent office for the use of
Thymosin beta 4 (Tβ4), its analogues, isoforms and other
derivatives in the treatment of infections and inflammatory
disorders including colitis, ileitis, gastrointestinal ulcers and
gingivitis, among others. The patent expires in 2023. This is one
of several patents the Company has been granted in Australia
related to its technology and drug candidates.
“We are pleased to enhance our global intellectual property
estate for our product candidates and their potential uses,” said
J.J. Finkelstein, president and CEO of RegeneRx Biopharmaceuticals.
“We currently have more than 60 issued patents and patent
applications throughout the world that expire between 2019 and
2027.”
About Tβ4
Tβ4 is a synthetic version of a naturally occurring peptide
present in virtually all human cells. It is a first-in-class
multi-functional molecule that has been shown in preclinical
studies to promote endothelial cell differentiation and migration
in the heart and central nervous system, promote angiogenesis in
dermal and cardiac tissues, increase keratinocyte migration and
collagen deposition, and decrease inflammation by down regulating
inflammatory cytokines. RegeneRx has identified several molecular
variations of Tβ4 that may affect the aging of skin, among other
properties, and could be important candidates as active ingredients
in pharmaceutical and consumer products. Researchers at the
National Institutes of Health and various academic researchers
throughout the world have published numerous scientific articles in
high-impact journals indicating Tβ4’s in vitro and in vivo efficacy
in accelerating wound healing and tissue protection and
regeneration under a variety of conditions. Abstracts of scientific
papers related to Tβ4’s mechanisms of action can be viewed at
www.regenerx.com.
About RegeneRx
Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. Currently RegeneRx has three products in
clinical development. RGN-352 is an injectable formulation to treat
cardiovascular and central nervous system diseases, as well as
other medical indications. RegeneRx has successfully completed a
Phase 1 clinical trial with RGN-352. RGN-259 is a sterile,
preservative-free topical eye drop for ophthalmic indications.
RegeneRx is currently supporting a physician-sponsored Phase 2 dry
eye study evaluating RGN-259. RGN-137, a topical gel formulation,
is currently being evaluated by RegeneRx in a Phase 2 clinical
trial for the treatment of epidermolysis bullosa. Other potential
uses for RGN-137 include the treatment of chronic dermal wounds and
reduction of scar tissue. Based on strong efficacy data in
preclinical studies, RegeneRx is initially targeting RGN-352 for
the treatment of patients who have suffered an acute myocardial
infarction, or heart attack. In addition to this indication, recent
preclinical efficacy data suggests that RGN-352 may also benefit
patients with multiple sclerosis and stroke. RegeneRx also has a
preclinical product candidate, RGN-457, which is an inhaled
formulation targeting cystic fibrosis and other pulmonary diseases.
In addition to the four pharmaceutical product candidates described
above, RegeneRx is pursuing the commercial development of peptide
fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds
more than 60 worldwide patents and patent applications related to
its products and an exclusive worldwide license for Tβ4 from the
National Institutes of Health.
Forward-Looking
Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve risks and uncertainties that
could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. You are urged to consider
statements that include the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,”
“would,” “could,” “will,” ”may,” “potential” or the negative of
those words or other similar expressions words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risks and uncertainties
inherent in our business, including, without limitation the risk
that our product candidates do not demonstrate safety and/or
efficacy in future clinical trials; risks related to our ability to
obtain financing to support our operations on commercially
reasonable terms; the progress, timing or success of our clinical
trials; difficulties or delays in development, testing, obtaining
regulatory approval for producing and marketing our product
candidates; regulatory developments; the size and growth potential
of the markets for our product candidates and our ability to serve
those markets; the scope and validity of patent protection for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and other risks described in the Company’s
filings with the Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” sections of the
annual report on Form 10-K for the year ended December 31, 2009,
filed with the SEC on March 31, 2009, and the quarterly report on
Form 10-Q for the quarter ended March 31, 2010, filed with the SEC
on May 17, 2010, as well as other filings it makes with the SEC.
Any forward-looking statements in this press release represent the
Company’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
The Company anticipates that subsequent events and developments may
cause its views to change, and the Company specifically disclaims
any obligation to update this information, as a result of future
events or otherwise, except as required by applicable law.
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024